Eli Lilly and Company's Q4 and full-year earnings showcased impressive growth, driven by tirzepatide's success, leading to a 45% revenue increase in Q4 and 32% for the year. Tirzepatide, marketed ...

Eli Lilly’s momentum stems from blockbuster GLP-1 therapies (Mounjaro, Zepbound), fuelling ... In terms of achieving the highest alpha, owning the stock for two years may be the shrewdest ...

Eli Lilly has begun the week with ... Tirzepatide, the GLP-1 drug in Mounjaro and Zepbound, is Lilly’s highest-profile MASH candidate. Lilly reported phase 2 MASH data in June and later outlined ...

Analysts had expected profit of $4.52 billion, or $4.99 per share, on $13.56 billion in revenue, per Visible Alpha. After adjusting for one-time costs, Eli Lilly's adjusted earnings per share (EPS ...

One of the highlights of Eli Lilly's third-quarter ... and the visible results that people experience." Mounjaro was approved by the FDA in May, becoming the first combined GLP-1/GIP agonist ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

Indianapolis-based Eli Lilly and ... treatment program. Lilly said the increase in U.S. volume was mostly driven by GLP-1 weight-loss blockbusters Zepbound and Mounjaro, partially offset by ...

with its GLP-1 class drugs, Mounjaro and Zepbound, driving prescription growth and solidifying its competitive edge. To support its growth ambitions, Eli Lilly and Company (NYSE:LLY) is investing ...

Mounjaro, in particular, has been outpacing its class of GLP-1 drugs ... billion is set to bolster Eli Lilly's oncology portfolio, particularly in advancing PI3K-alpha mutant selective therapies ...